Muller and coworkers reported previously that SEMA3A treatment of pancreas cancer cells increases phospho-Erk levels but not expression levels of MMP2, MMP9, or markers of EMT, and suggest that these are, in a ‘pancreas cancer-specific character’ not a part of SEMA3A downstream signaling in pancreatic cancer cells [12]. This evidence concerns the gene SEMA3A and familial pancreatic carcinoma.